Data Generated to Date Support Potential for Aclaris’ ATI-2138 to Impact Several Human Inflammatory Diseases - WAYNE, Pa., ...

Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has announced significant findings about ATI-2138, a novel investigational drug ...

Aclaris Therapeutics (ACRS) announced the availability of a new publication describing properties of Aclaris Therapeutics’ ATI-2138, a novel ...

The UL13 protein of herpesviruses is conserved among all herpesviruses and is a serine/threonine protein kinase, which plays a vital role in escaping innate ... Based on these results, whether the ...

Accropeutics Inc. (Accropeutics), a clinical-stage biotechnology company pioneering the development of novel therapeutics that target molecular mechanisms of regulated cell death for immune mediated ...

DelveInsight’s, “Metastatic Colorectal Cancer Pipeline Insight” report provides comprehensive insights about 80+ companies ...

1Department of Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 2The University of Texas MD Anderson Cancer Center, UTHealth Houston Graduate ...

One such strategy is to repurpose FDA-approved kinase inhibitors that are potential chemotherapeutic agents and have demonstrated ... It is an antiparasitic and antiviral medication. It was found to ...

zju.edu.cn Objective Raf kinase inhibitor protein (RKIP) appears to control cancer cell metastasis and its ... and the mice were assessed based on colitis symptoms and biochemical approaches. The ...

but no clear specific mechanism of action. It appears to be a mild monoamine oxidase inhibitor, a mild serotonin reuptake blocker, and consist of other psychotropic compounds and actions yet to be ...